- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
Academic Institute
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative breast ... Read more >
Status: Enrolling
Investigator: Warren Ellsworth
Study Coordinator: Valentina Villarroel
Phone: 346.238.4384
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparative a... Read more >
Status: Enrolling
Investigator: Aldona Spiegel
Study Coordinator: Valentina Villarroel
Phone: 346.238.4384
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparative a... Read more >
Status: Open Not Enrolling
Investigator: Hanh Mai
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This ... Read more >
Status: Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizum... Read more >
Status: Open Not Enrolling
Investigator: Sandra Templeton
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes that ca... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whe... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug tha... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, s... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.... Read more >
Status: Open Not Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologi... Read more >
Status: Open Not Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive loc... Read more >
Status: Open Not Enrolling
Investigator: Hanh Mai
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Anne McCombs
Phone: 713.441.0528
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistoche... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is completed... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Givin... Read more >
Status: Open Not Enrolling
Investigator: Kai Sun
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresecta... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
Hormone receptor positive breast cancer HRBC is the most common cause of BC-related death. HRBC is characterized by a non-immunogenic microenvironment and consequently, modest responses have been observed with immune checkpoint blockade ICB alone or ... Read more >
Status: Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective.... Read more >
Status: Enrolling
Investigator: Hanh Mai
Study Coordinator: Natolie Hamilton
Phone: 469.267.9275
This phase III clinical trial will evaluate the impact on survival of adding chaplain-provided spiritual care or psychotherapy/meditation to standard-of-care (SOC) and palliative measures, plus chemotherapy if recommended, and comparing it with SOC a... Read more >
Status: Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this causes... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). Th... Read more >
Status: Enrolling
Investigator: Kai Sun
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembr... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens.... Read more >
Status: Open Not Enrolling
Investigator: Sindhu Nair
Study Coordinator: Misbah Baloch
Phone: 713.790.3311
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-posi... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestan... Read more >
Status: Enrolling
Investigator: Bin Teh
Study Coordinator: Natolie Hamilton
Phone: 469.267.9275
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation tr... Read more >
Status: Open Not Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzuma... Read more >